Celldex announces prices of underwritten public offering of common stock Celldex Therapeutics.

Jefferies & Organization, Inc. Is performing as the only real book-running manager of the supplying. Wedbush PacGrow Lifestyle Sciences, Oppenheimer & Co., Brean Murray, Carret & Co. And Roth Capital Companions, LLC are acting as co-managers of the offering. Celldex anticipates using the net proceeds from the offering to invest in Celldex’s medical trials of its item candidates and for working capital and various other general corporate purposes.. Celldex announces prices of underwritten public offering of common stock Celldex Therapeutics, Inc. today announced the prices of an underwritten public offering of 10,500,000 shares of its common stock, offered by a price to the general public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.Capricor is recruiting individuals to its ALLSTAR Trial presently, a Phase I/II medical trial involving 274 sufferers who have suffered large heart attacks. The Phase I part of the trial has been funded partly by a grant from the National Institutes of Wellness . Both awards are non-dilutive to the Capricor shareholders, but the CIRM award is normally at the mercy of repayment. Capricor's and Nile's product portfolios complement one another well, as our therapies will address both the underlying causes and debilitating ramifications of heart disease, said Linda Marban, Ph.D., CEO of Capricor, Inc.